Shopping Cart 0
Cart Subtotal
AED 0

KOL Perspectives: Novel treatment options for moderate UC

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

KOL Perspectives: Novel treatment options for moderate UC

Summary

This KOL Insight briefing focuses on KOLs views of novel treatment options for moderate UC.

The briefing includes analysis of KOL opinion on the following topic areas-

- Current clinical management of moderate UC patients

- Awareness of novel therapies in development suitable for moderate UC

- Perception of Phase II apremilast data in moderate UC

- Expectations for treatment algorithm positioning of apremilast

- Potential for future combination therapy with apremilast

- Perception of apremilast's other labels in psoriasis (PsO) and psoriatic arthritis (PsA)

Key Highlights

- Nearly half of all UC patients seen in the majority of KOLs' clinical practices are considered as having moderate UC

- Most KOLs would initially treat moderate UC patients with 5-ASAs, moving to anti-TNF therapies if patients do not respond

- KOLs stated that less than 10% of moderate UC patients required surgical intervention.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during March 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "novel treatment options for moderate UC"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

UC, apremilast, comorbidities


Companies

Celgene

Company Profile

Company Profile Title

KOL Perspectives: Novel treatment options for moderate UC

Summary

This KOL Insight briefing focuses on KOLs views of novel treatment options for moderate UC.

The briefing includes analysis of KOL opinion on the following topic areas-

- Current clinical management of moderate UC patients

- Awareness of novel therapies in development suitable for moderate UC

- Perception of Phase II apremilast data in moderate UC

- Expectations for treatment algorithm positioning of apremilast

- Potential for future combination therapy with apremilast

- Perception of apremilast's other labels in psoriasis (PsO) and psoriatic arthritis (PsA)

Key Highlights

- Nearly half of all UC patients seen in the majority of KOLs' clinical practices are considered as having moderate UC

- Most KOLs would initially treat moderate UC patients with 5-ASAs, moving to anti-TNF therapies if patients do not respond

- KOLs stated that less than 10% of moderate UC patients required surgical intervention.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during March 2018

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "novel treatment options for moderate UC"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of UC

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

UC, apremilast, comorbidities


Companies

Celgene